Update of the human and mouse fanconi anemia genes

Human Genomics

Volumn 9, Issue 1, 2015, Pages

  Dong, Hongbin ^a   Nebert, Daniel W ^b   Bruford, Elspeth A ^c   Thompson, David C ^d   Joenje, Hans ^e   Vasiliou, Vasilis ^a  

^a YALE UNIVERSITY   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^c EUROPEAN BIOINFORMATICS INSTITUTE   (United Kingdom)

^d UNIVERSITY OF COLORADO   (United States)

^e VUmc Institute for Cancer and Immunology V ICI   (Netherlands)

Author keywords

Classification; Fanconi anemia; Genes; Genome; Human; Mouse

Indexed keywords

FANCONI ANEMIA PROTEIN; MUTANT PROTEIN;

DNA REPAIR; FANCONI ANEMIA; GENOMIC INSTABILITY; GENOMICS; HUGO GENE NOMENCLATURE; HUMAN; MOLECULAR PHYLOGENY; MOUSE; NONHUMAN; PATHOGENESIS; REVIEW; ANIMAL; BONE MARROW; DNA DAMAGE; GENETICS; METABOLISM; MOLECULAR EVOLUTION; NEOPLASM; PATHOPHYSIOLOGY;

ANIMALS; BONE MARROW; DNA DAMAGE; DNA REPAIR; EVOLUTION, MOLECULAR; FANCONI ANEMIA; FANCONI ANEMIA COMPLEMENTATION GROUP PROTEINS; HUMANS; MICE; NEOPLASMS;

EID: 84947814737     PISSN: 14739542     EISSN: 14797364     Source Type: Journal    
DOI: 10.1186/s40246-015-0054-y     Document Type: Review

References (90)

1. Mathew CG. Fanconi anaemia genes and susceptibility to cancer. Oncogene. 2006;25(43):5875–84.
2. Barankin B, Metelitsa AI, Schloss EH, Wasel NR. Skin disorders in Ashkenazi Jews: a review. Int J Dermatol. 2005;44(8):630–5.
3. Tipping AJ, Pearson T, Morgan NV, Gibson RA, Kuyt LP, Havenga C, et al. Molecular and genealogical evidence for a founder effect in Fanconi anemia families of the Afrikaner population of South Africa. Proc Natl Acad Sci U S A. 2001;98(10):5734–9.
4. Whitney MA, Jakobs P, Kaback M, Moses RE, Grompe M. The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population. Hum Mutat. 1994;3(4):339–41.
5. Alter BP, and Kupfer G (1993–2015) Fanconi Anemia. In: Pagon RA, Adam MP, Ardinger HH, Wallace SE, Amemiya A, Bean LJH, Bird TD, Dolan CR, Fong CT, Smith RJH, Stephens K, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle. Available From http://www.ncbi.nlm.nih.gov/books/NBK1401/ Access date February 7, 2013.
6. Wang LC, Gautier J. The Fanconi anemia pathway and ICL repair: implications for cancer therapy. Crit Rev Biochem Mol Biol. 2010;45(5):424–39.
7. Meetei AR, Levitus M, Xue Y, Medhurst AL, Zwaan M, Ling C, et al. X-linked inheritance of Fanconi anemia complementation group B. Nat Genet. 2004;36(11):1219–24.
8. Yung SK, Tilgner K, Ledran MH, Habibollah S, Neganova I, Singhapol C, et al. Brief report: human pluripotent stem cell models of Fanconi anemia deficiency reveal an important role for Fanconi anemia proteins in cellular reprogramming and survival of hematopoietic progenitors. Stem Cells. 2013;31(5):1022–9.
9. Alter BP. Fanconi anemia and the development of leukemia. Best Pract Res Clin Haematol. 2014;27(3–4):214–21.
10. Lobitz S, Velleuer E. Guido Fanconi (1892–1979): a jack of all trades. Nat Rev Cancer. 2006;6(11):893–8.
11. Rogers KJ, Fu W, Akey JM, Monnat Jr RJ. Global and disease-associated genetic variation in the human Fanconi anemia gene family. Hum Mol Genet. 2014;23(25):6815–25.
12. Strathdee CA, Gavish H, Shannon WR, Buchwald M. Cloning of cDNAs for Fanconi’s anaemia by functional complementation. Nature. 1992;356(6372): 763–7.
13. Lo Ten Foe JR, Rooimans MA, Bosnoyan-Collins L, Alon N, Wijker M, Parker L, et al. Expression cloning of a cDNA for the major Fanconi anaemia gene, FAA. Nat Genet. 1996;14(3):320–3.
14. de Winter JP, Waisfisz Q, Rooimans MA, van Berkel CG, Bosnoyan-Collins L, Alon N, et al. The Fanconi anaemia group G gene FANCG is identical with XRCC9. Nat Genet. 1998;20(3):281–3.
15. de Winter JP, Rooimans MA, van Der WL, van Berkel CG, Alon N, Bosnoyan-Collins L, et al. The Fanconi anaemia gene FANCF encodes a novel protein with homology to ROM. Nat Genet. 2000;24(1):15–6.
16. de Winter JP, Leveille F, van Berkel CG, Rooimans MA, van Der WL, Steltenpool J, et al. Isolation of a cDNA representing the Fanconi anemia complementation group E gene. Am J Hum Genet. 2000;67(5):1306–8.
17. Schneider M, Chandler K, Tischkowitz M, Meyer S. Fanconi anaemia: genetics, molecular biology, and cancer––implications for clinical management in children and adults. Clin Genet. 2014;88(1):13–24.
18. Solomon PJ, Margaret P, Rajendran R, Ramalingam R, Menezes GA, Shirley AS, et al. A case report and literature review of Fanconi Anemia (FA) diagnosed by genetic testing. Ital J Pediatr. 2015;41:38.
19. Pang Q, Christianson TA, Keeble W, Diaz J, Faulkner GR, Reifsteck C, et al. The Fanconi anemia complementation group C gene product: structural evidence of multifunctionality. Blood. 2001;98(5):1392–401.
20. Kutler DI, Auerbach AD. Fanconi anemia in Ashkenazi Jews. Fam Cancer. 2004;3(3–4):241–8.
21. Yagasaki H, Oda T, Adachi D, Nakajima T, Nakahata T, Asano S, et al. Two common founder mutations of the Fanconi anemia group G gene FANCG/ XRCC9 in the Japanese population. Hum Mutat. 2003;21(5):555.
22. Park J, Chung NG, Chae H, Kim M, Lee S, Kim Y, et al. FANCA and FANCG are the major Fanconi anemia genes in the Korean population. Clin Genet. 2013;84(3):271–5.
23. Moldovan GL, D’Andrea AD. How the Fanconi anemia pathway guards the genome. Annu Rev Genet. 2009;43:223–49.
24. Howlett NG, Taniguchi T, Olson S, Cox B, Waisfisz Q, De Die-Smulders C, et al. Biallelic inactivation of BRCA2 in Fanconi anemia. Science. 2002;297(5581):606–9.
25. Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12(5):245–59.
26. Smetsers S, Muter J, Bristow C, Patel L, Chandler K, Bonney D, et al. Heterozygote FANCD2 mutations associated with childhood T Cell ALL and testicular seminoma. Fam Cancer. 2012;11(4):661–5.
27. Flynn EK, Kamat A, Lach FP, Donovan FX, Kimble DC, Narisu N, et al. Comprehensive analysis of pathogenic deletion variants in Fanconi anemia genes. Hum Mutat. 2014;35(11):1342–53.
28. Waisfisz Q, Saar K, Morgan NV, Altay C, Leegwater PA, de Winter JP, et al. The Fanconi anemia group E gene, FANCE, maps to chromosome 6p. Am J Hum Genet. 1999;64(5):1400–5.
29. Gille JJ, Floor K, Kerkhoven L, Ameziane N, Joenje H, de Winter JP. Diagnosis of Fanconi anemia: mutation analysis by multiplex ligation-dependent probe amplification and PCR-based Sanger sequencing. Anemia. 2012;2012: 603253.
30. Sims AE, Spiteri E, Sims III RJ, Arita AG, Lach FP, Landers T, et al. FANCI is a second monoubiquitinated member of the Fanconi anemia pathway. Nat Struct Mol Biol. 2007;14(6):564–7.
31. Colnaghi L, Jones MJ, Cotto-Rios XM, Schindler D, Hanenberg H, Huang TT. Patient-derived C-terminal mutation of FANCI causes protein mislocalization and reveals putative EDGE motif function in DNA repair. Blood. 2011;117(7): 2247–56.
32. Wu Y, Sommers JA, Suhasini AN, Leonard T, Deakyne JS, Mazin AV, et al. Fanconi anemia group J mutation abolishes its DNA repair function by uncoupling DNA translocation from helicase activity or disruption of protein-DNA complexes. Blood. 2010;116(19):3780–91.
33. Guo M, Vidhyasagar V, Ding H, Wu Y. Insight into the roles of helicase motif Ia by characterizing Fanconi anemia group J protein (FANCJ) patient mutations. J Biol Chem. 2014;289(15):10551–65.
34. Ameziane N, Sie D, Dentro S, Ariyurek Y, Kerkhoven L, Joenje H, et al. Diagnosis of Fanconi anemia: mutation analysis by next-generation sequencing. Anemia. 2012;2012:132856.
35. Garcia MJ, Fernandez V, Osorio A, Barroso A, Fernandez F, Urioste M, et al. Mutational analysis of FANCL, FANCM and the recently identified FANCI suggests that among the 13 known Fanconi anemia genes, only FANCD1/ BRCA2 plays a major role in high-risk breast cancer predisposition. Carcinogenesis. 2009;30(11):1898–902.
36. Reid S, Schindler D, Hanenberg H, Barker K, Hanks S, Kalb R, et al. Biallelic mutations in PALB2 cause Fanconi anemia subtype FA-N and predispose to childhood cancer. Nat Genet. 2007;39(2):162–4.
37. Lim ET, Wurtz P, Havulinna AS, Palta P, Tukiainen T, Rehnstrom K, et al. Distribution and medical impact of loss-of-function variants in the Finnish founder population. PLoS Genet. 2014;10(7):e1004494.
38. Meindl A, Hellebrand H, Wiek C, Erven V, Wappenschmidt B, Niederacher D, et al. Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene. Nat Genet. 2010;42(5):410–4.
39. Kim Y, Lach FP, Desetty R, Hanenberg H, Auerbach AD, Smogorzewska A. Mutations of the SLX4 gene in Fanconi anemia. Nat Genet. 2011;43(2):142–6.
40. de Garibay GR, Diaz A, Gavina B, Romero A, Garre P, Vega A, et al. Low prevalence of SLX4 loss-of-function mutations in non-BRCA1/2 breast and/or ovarian cancer families. Eur J Hum Genet. 2013;21(8):883–6.
41. Bogliolo M, Schuster B, Stoepker C, Derkunt B, Su Y, Raams A, et al. Mutations in ERCC4, encoding the DNA-repair endonuclease XPF, cause Fanconi anemia. Am J Hum Genet. 2013;92(5):800–6.
42. Sawyer SL, Tian L, Kahkonen M, Schwartzentruber J, Kircher M, Majewski J, et al. Biallelic mutations in BRCA1 cause a new Fanconi anemia subtype. Cancer Discov. 2015;5(2):135–42.
43. Stecklein SR, Jensen RA. Identifying and exploiting defects in the Fanconi anemia/BRCA pathway in oncology. Transl Res. 2012;160(3):178–97.
44. Domchek SM, Tang J, Stopfer J, Lilli DR, Hamel N, Tischkowitz M, et al. Biallelic deleterious BRCA1 mutations in a woman with early-onset ovarian cancer. Cancer Discov. 2013;3(4):399–405.
45. Jasin M, Rothstein R. Repair of strand breaks by homologous recombination. Cold Spring Harb Perspect Biol. 2013;5(11):a012740.
46. Wang AT, Kim T, Wagner JE, Conti BA, Lach FP, Huang AL, et al. A dominant mutation in human RAD51 reveals its function in DNA interstrand crosslink repair independent of homologous recombination. Mol Cell. 2015;59(3):478–90.
47. Machida YJ, Machida Y, Chen Y, Gurtan AM, Kupfer GM, D’Andrea AD, et al. UBE2T is the E2 in the Fanconi anemia pathway and undergoes negative autoregulation. Mol Cell. 2006;23(4):589–96.
48. Hira A, Yoshida K, Sato K, Okuno Y, Shiraishi Y, Chiba K, et al. Mutations in the gene encoding the E2 conjugating enzyme UBE2T cause Fanconi anemia. Am J Hum Genet. 2015;96(6):1001–7.
49. Titus TA, Selvig DR, Qin B, Wilson C, Starks AM, Roe BA, et al. The Fanconi anemia gene network is conserved from zebrafish to human. Gene. 2006;371(2):211–23.
50. Marek LR, Bale AE. Drosophila homologs of FANCD2 and FANCL function in DNA repair. DNA Repair (Amst). 2006;5(11):1317–26.
51. Meetei AR, Medhurst AL, Ling C, Xue Y, Singh TR, Bier P, et al. A human ortholog of archaeal DNA repair protein Hef is defective in Fanconi anemia complementation group M. Nat Genet. 2005;37(9):958–63.
52. Lo T, Pellegrini L, Venkitaraman AR, Blundell TL. Sequence fingerprints in BRCA2 and RAD51: implications for DNA repair and cancer. DNA Repair (Amst). 2003;2(9):1015–28.
53. Petalcorin MI, Sandall J, Wigley DB, Boulton SJ. CeBRC-2 stimulates D-loop formation by RAD-51 and promotes DNA single-strand annealing. J Mol Biol. 2006;361(2):231–42.
54. Collis SJ, Barber LJ, Ward JD, Martin JS, Boulton SJ. C. elegans FANCD2 responds to replication stress and functions in interstrand cross-link repair. DNA Repair (Amst). 2006;5(11):1398–406.
55. Youds JL, Barber LJ, Ward JD, Collis SJ, O’Neil NJ, Boulton SJ, et al. DOG-1 is the Caenorhabditis elegans BRIP1/FANCJ homologue and functions in interstrand cross-link repair. Mol Cell Biol. 2008;28(5):1470–9.
56. Daee DL, Myung K. Fanconi-like crosslink repair in yeast. Genome Integr. 2012;3(1):7.
57. Ward TA, Dudasova Z, Sarkar S, Bhide MR, Vlasakova D, Chovanec M, et al. Components of a Fanconi-like pathway control Pso2-independent DNA interstrand crosslink repair in yeast. PLoS Genet. 2012;8(8):e1002884.
58. Knoll A, Higgins JD, Seeliger K, Reha SJ, Dangel NJ, Bauknecht M, et al. The Fanconi anemia ortholog FANCM ensures ordered homologous recombination in both somatic and meiotic cells in Arabidopsis. Plant Cell. 2012;24(4):1448–64.
59. Zhang XY, Langenick J, Traynor D, Babu MM, Kay RR, Patel KJ. Xpf and not the Fanconi anaemia proteins or Rev3 accounts for the extreme resistance to cisplatin in Dictyostelium discoideum. PLoS Genet. 2009;5(9):e1000645.
60. Houghtaling S, Timmers C, Noll M, Finegold MJ, Jones SN, Meyn MS, et al. Epithelial cancer in Fanconi anemia complementation group D2 (Fancd2) knockout mice. Genes Dev. 2003;17(16):2021–35.
61. Whitney MA, Royle G, Low MJ, Kelly MA, Axthelm MK, Reifsteck C, et al. Germ cell defects and hematopoietic hypersensitivity to gamma-interferon in mice with a targeted disruption of the Fanconi anemia C gene. Blood. 1996;88(1):49–58.
62. Hakem R, de la Pompa JL, Mak TW. Developmental studies of Brca1 and Brca2 knock-out mice. J Mammary Gland Biol Neoplasia. 1998;3(4):431–45.
63. Cheng NC, van de Vrugt HJ, van der Valk MA, Oostra AB, Krimpenfort P, de VY, et al. Mice with a targeted disruption of the Fanconi anemia homolog Fanca. Hum Mol Genet. 2000;9:1805–11.
64. Yang Y, Kuang Y, De Montes OR, Hays T, Moreau L, Lu N, et al. Targeted disruption of the murine Fanconi anemia gene, Fancg/Xrcc9. Blood. 2001;98(12):3435–40.
65. Wong JC, Alon N, Mckerlie C, Huang JR, Meyn MS, Buchwald M. Targeted disruption of exons 1 to 6 of the Fanconi Anemia group A gene leads to growth retardation, strain-specific microphthalmia, meiotic defects and primordial germ cell hypoplasia. Hum Mol Genet. 2003;12(16):2063–76.
66. Bakker ST, van de Vrugt HJ, Rooimans MA, Oostra AB, Steltenpool J, Delzenne-Goette E, et al. Fancm-deficient mice reveal unique features of Fanconi anemia complementation group M. Hum Mol Genet. 2009;18(18): 3484–95.
67. Bouwman P, Drost R, Klijn C, Pieterse M, van der Gulden H, Song JY, et al. Loss of p53 partially rescues embryonic development of Palb2 knockout mice but does not foster haploinsufficiency of Palb2 in tumour suppression. J Pathol. 2011;224(1):10–21.
68. Bakker ST, van de Vrugt HJ, Visser JA, Delzenne-Goette E, van der Wal A, Berns MA, et al. Fancf-deficient mice are prone to develop ovarian tumours. J Pathol. 2012;226(1):28–39.
69. Taniguchi T, D’Andrea AD. The Fanconi anemia protein, FANCE, promotes the nuclear accumulation of FANCC. Blood. 2002;100(7):2457–62.
70. Polito D, Cukras S, Wang X, Spence P, Moreau L, D’Andrea AD, et al. The carboxyl terminus of FANCE recruits FANCD2 to the Fanconi Anemia (FA) E3 ligase complex to promote the FA DNA repair pathway. J Biol Chem. 2014;289(10):7003–10.
71. Gurtan AM, Stuckert P, D’Andrea AD. The WD40 repeats of FANCL are required for Fanconi anemia core complex assembly. J Biol Chem. 2006; 281(16):10896–905.
72. Joksic I, Vujic D, Guc-Scekic M, Leskovac A, Petrovic S, Ojani M, et al. Dysfunctional telomeres in primary cells from Fanconi anemia FANCD2 patients. Genome Integr. 2012;3(1):6.
73. Garaycoechea JI, Patel KJ. Why does the bone marrow fail in Fanconi anemia? Blood. 2014;123(1):26–34.
74. Howard SM, Yanez DA, Stark JM. DNA damage response factors from diverse pathways, including DNA crosslink repair, mediate alternative end joining. PLoS Genet. 2015;11(1):e1004943.
75. Otsuki T, Furukawa Y, Ikeda K, Endo H, Yamashita T, Shinohara A, et al. Fanconi anemia protein, FANCA, associates with BRG1, a component of the human SWI/SNF complex. Hum Mol Genet. 2001;10(23):2651–60.
76. Sridharan D, Brown M, Lambert WC, McMahon LW, Lambert MW. Nonerythroid alpha II spectrin is required for recruitment of FANCA and XPF to nuclear foci induced by DNA interstrand cross-links. J Cell Sci. 2003;116(Pt 5):823–35.
77. Ravera S, Vaccaro D, Cuccarolo P, Columbaro M, Capanni C, Bartolucci M, et al. Mitochondrial respiratory chain Complex I defects in Fanconi anemia complementation group A. Biochimie. 2013;95(10):1828–37.
78. Kim S, Hwang SK, Lee M, Kwak H, Son K, Yang J, et al. Fanconi anemia complementation group A (FANCA) localizes to centrosomes and functions in the maintenance of centrosome integrity. Int J Biochem Cell Biol. 2013;45(9):1953–61.
79. Scharer OD. DNA interstrand crosslinks: natural and drug-induced DNA adducts that induce unique cellular responses. Chembiochem. 2005;6(1):27–32.
80. Castillo P, Bogliolo M, Surralles J. Coordinated action of the Fanconi anemia and ataxia telangiectasia pathways in response to oxidative damage. DNA Repair (Amst). 2011;10(5):518–25.
81. Taniguchi T, Garcia-Higuera I, Xu B, Andreassen PR, Gregory RC, Kim ST, et al. Convergence of theFanconi anemia and ataxia telangiectasia signaling pathways. Cell. 2002;109(4):459–72.
82. Nakanishi K, Taniguchi T, Ranganathan V, New HV, Moreau LA, Stotsky M, et al. Interaction of FANCD2 and NBS1 in the DNA damage response. Nat Cell Biol. 2002;4(12):913–20.
83. Deans AJ, West SC. FANCM connects the genome instability disorders Bloom’s syndrome and Fanconi anemia. Mol Cell. 2009;36(6):943–53.
84. Alter BP. Cancer in Fanconi anemia, 1927–2001. Cancer. 2003;97(2):425–40.
85. Gillio AP, Verlander PC, Batish SD, Giampietro PF, Auerbach AD. Phenotypic consequences of mutations in the Fanconi anemia FANCC gene: an International Fanconi Anemia Registry study. Blood. 1997;90(1):105–10.
86. Futaki M, Yamashita T, Yagasaki H, Toda T, Yabe M, Kato S, et al. The IVS4 + 4 A to T mutation of the Fanconi anemia gene FANCC is not associated with a severe phenotype in Japanese patients. Blood. 2000;95(4):1493–8.
87. Wagner JE, Tolar J, Levran O, Scholl T, Deffenbaugh A, Satagopan J, et al. Germline mutations in BRCA2: shared genetic susceptibility to breast cancer, early onset leukemia, and Fanconi anemia. Blood. 2004;103(8):3226–9.
88. Akbari MR, Malekzadeh R, Lepage P, Roquis D, Sadjadi AR, Aghcheli K, et al. Mutations in Fanconi anemia genes and the risk of esophageal cancer. Hum Genet. 2011;129(5):573–82.
89. Couch FJ, Johnson MR, Rabe K, Boardman L, McWilliams R, de AM, et al. Germ line Fanconi anemia complementation group C mutations and pancreatic cancer. Cancer Res. 2005;65(2):383–6.
90. Rafnar T, Gudbjartsson DF, Sulem P, Jonasdottir A, Sigurdsson A, Jonasdottir A, et al. Mutations in BRIP1 confer high risk of ovarian cancer. Nat Genet. 2011;43(11):1104–7.